Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6510098 | 0.93 | LMNA (0.46) | LMNAKDM4EMAPK1SMN1; SMN2FABP4 | |
| SCHEMBL27801037 | 0.90 | LMNA (0.54) | LMNAKDM4EMAPK1SMN1; SMN2CNR2 | |
| SCHEMBL7365093 | 0.85 | FABP4 (0.51) | MAPK1SMN1; SMN2FABP4FABP5MEN1 | |
| SCHEMBL7633464 | 0.79 | FABP4 (0.53) | MAPK1SMN1; SMN2FABP4FABP5MEN1 | |
| SCHEMBL4960220 | 0.78 | CA12 (0.42) | LMNAKDM4ESMN1; SMN2MEN1KMT2A | |
| Naphthalene SCHEMBL28931578 | 0.77 | LMNA (0.50) | LMNAKDM4ESMN1; SMN2MEN1KMT2A | |
| SCHEMBL7634312 | 0.76 | KMO (0.50) | LMNAKDM4EFABP4FABP5MEN1 | |
| SCHEMBL11801475 | 0.75 | HEXA (0.42) | — | |
| SCHEMBL5729887 | 0.74 | ALDH1A1 (0.44) | LMNAKDM4EMAPK1SMN1; SMN2CNR2 | |
| SCHEMBL931997 | 0.74 | TBXAS1 (0.38) | LMNAFABP4FABP5ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187572-A1 | Matrix Metalloproteinase Inhibitors of Tgfb-Induced Subcapsular Cataract Formation | MCMASTER UNIVERSITY (CA) | 2008-08-07 | — | — | US | claimed |
| EP-1877051-A1 | MATRIX METALLOPROTEINASE INHIBITORS OF TGFß -INDUCED SUBCAPSULAR CATARACT FORMATION | McMaster University (CA) | 2008-01-16 | — | — | EP | claimed |
| WO-2006113993-A1 | MATRIX METALLOPROTEINASE INHIBITORS OF TGFß -INDUCED SUBCAPSULAR CATARACT FORMATION | MCMASTER UNIVERSITY (CA) | 2006-11-02 | — | — | WO | claimed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20130012683-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040199241-A1 | Silk stent grafts | ANGIOTECH INTERNATIONAL AG (CH) | 2004-10-07 | — | — | US | disclosed |
| US-20040192658-A1 | Compositions and methods of using collajolie | ANGIOTECH INTERNATIONAL AG (CH) | 2004-09-30 | — | — | US | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060405-A2 | TISSUE REACTIVE COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060424-A2 | SILK-CONTAINING STENT GRAFT | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060425-A2 | COMPOSITIONS AND METHODS OF USING COLLAGEN AND MMPI | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | CD44, SELP, EPCAM | LMNA 3608/4885KDM4E 4637/4885MAPK1 2794/4885 |
| US-20040192658-A1 | Compositions and methods of using collajolie | MMP9, COL2A1, MMP1 | LMNA 414/4885KDM4E 1055/4885MAPK1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.